Everolimus-eluting stent curbs thrombosis, mortality risk in diabetes

11/29/2012 | Healio

Diabetes patients who were implanted with a second-generation everolimus-eluting stent showed lower stent thrombosis rates and all-cause mortality compared with those who had first-generation sirolimus-eluting and paclitaxel-eluting stents, a study indicated. The results appear in the Journal of the American College of Cardiology: Cardiovascular Interventions.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ